Share

October 02, 2012; 79 (14) Articles

Large-scale neuronal network dysfunction in relapsing-remitting multiple sclerosis

Maria A. Rocca, Paola Valsasina, Vittorio Martinelli, Paolo Misci, Andrea Falini, Giancarlo Comi, Massimo Filippi
First published September 5, 2012, DOI: https://doi.org/10.1212/WNL.0b013e31826d5f10
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
662

Share

Article Information

vol. 79 no. 14 1449-1457
DOI: 
https://doi.org/10.1212/WNL.0b013e31826d5f10
PubMed: 
22955126
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received December 19, 2011
  • Accepted April 6, 2012
  • First Published September 5, 2012.

Article Versions

Copyright & Usage: 
Copyright © 2012 by AAN Enterprises, Inc.

Author Disclosures

    1. Maria A. Rocca, MD,
    2. Paola Valsasina, MSc,
    3. Vittorio Martinelli, MD,
    4. Paolo Misci, MSc,
    5. Andrea Falini, MD,
    6. Giancarlo Comi, MD and
    7. Massimo Filippi, MD
  1. Maria A. Rocca, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Serves as consultant to Bayer Schering Pharma Speakers’ Bureaus: Received speakers’ bureaus for Biogen-Dompé AG

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Italian Ministry of Health GR-2008-1138784, PI, from 2011 to 2013 GR-2009-1529671, PI, from 2012 to 2014

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Paola Valsasina, MSc,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Vittorio Martinelli, MD,
    4. Scientific Advisory Boards:

    1. Served on the scientific advisory board for Merck Serono (20011-2012)

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Dr Martinelli has received travel supports and speaker fees for activities with Biogen Dompè, Merck/Serono,Genzyme Europe,Bayer Schering, Teva and Sanofi Aventis.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Paolo Misci, MSc,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Andrea Falini, MD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Giancarlo Comi, MD and
    7. Scientific Advisory Boards:

    1. In the last two years, I have received personal compensation as a member of Scientific Advisory Boards from commercial entities: 1)Bayer Schering, 2) Merck Serono International, 3) TEVA Pharmaceutical Ind. Ltd., 4) Sanofi-Aventis, 5) Novartis and 6) Biogen, 7) Actelion

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. In the past two years I have received honoraria for speaking activities from 1) TEVA Pharmaceutical Ind. Ltd, 2) Sanofi-Aventis, 3) Serono Symposia International Foundation, 4) Biogen-Dompè, 5) Merck Serono, 6)Novartis and 7)Bayer Schering 8) Actelion

    Editorial Boards:

    1. 1) Neurological Sciences, associate editor, 2011-2012

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. In the last two years, I have received personal compensation as a member of Scientific Advisory Boards from commercial entities: 1)Bayer Schering, 2) Merck Serono International, 3) TEVA Pharmaceutical Ind. Ltd., 4) Sanofi-Aventis, 5) Novartis and 6) Biogen, 7) Actelion

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Massimo Filippi, MD
    8. Scientific Advisory Boards:

    1. TEVA, Genmab

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Bayer-Schering, Biogen-Dompè, Genmab, Merck-Serono, Teva

    Editorial Boards:

    1. Editor in CHief, Journal of Neurology. Editorial Board Member: AJNR, BMC Musculoskeletal Disorders, Clinical Neurology and Neurosurgery, Erciyes Medical Journal, Journal of Alzheimer’s Disease, Journal of Neuroimaging, Journal of Neurovirology, Lancet Neurology, Magnetic Resonance Imaging, Multiple Sclerosis, Neurological Sciences

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Consultancies: Bayer-Schering, Biogen-Dompè, Genmab, Merck-Serono, Teva Speakers’ Bureaus: Bayer-Schering, Biogen-Dompè, Genmab, Merck-Serono, Teva.

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Grant/research support from: 1) Commercial entity: Bayer-Schering 2) Commercial entity: Biogen-Dompè 3) Commercial entity: Genmab 4) Commercial entity: Merck-Serono 5) Commercial entity: Teva

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Fondazione Italiana Sclerosi Multipla (FISM)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Neuroimaging Research Unit, Institute of Experimental Neurology (M.A.R., P.V., P.M., M.F.), Department of Neurology (M.A.R., V.M., G.C., M.F.), and Department of Neuroradiology (A.F.), San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
  1. Correspondence & reprint requests to Prof. Filippi: m.filippi{at}hsr.it
View Full Text

Article usage

Article usage: September 2012 to May 2022

AbstractFullPdfSource
Sep 2012427072Highwire
Oct 201214574481Highwire
Nov 20121781725Highwire
Dec 2012130318Highwire
Jan 20131231311Highwire
Feb 2013691017Highwire
Mar 20137498Highwire
Apr 2013603539Highwire
May 201344919Highwire
Jun 2013371122Highwire
Jul 201337812Highwire
Aug 20133275Highwire
Sep 20133685Highwire
Oct 201355514Highwire
Nov 201350710Highwire
Dec 20135310Highwire
Jan 20142567Highwire
Feb 201428913Highwire
Mar 20143657Highwire
Apr 20145747Highwire
May 201435411Highwire
Jun 20142836Highwire
Jul 20148798Highwire
Aug 20141657Highwire
Sep 20142698Highwire
Oct 20142211Highwire
Nov 20141852Highwire
Dec 20143272Highwire
Jan 20153047Highwire
Feb 20154689Highwire
Mar 20154179Highwire
Apr 20151833Highwire
May 20152028Highwire
Jun 20151237Highwire
Jul 20152511Highwire
Aug 20152465Highwire
Sep 20154013Highwire
Oct 201526108Highwire
Nov 201521511Highwire
Dec 20152913Highwire
Jan 20162234Highwire
Feb 20162023Highwire
Mar 20165025Highwire
Apr 20162767Highwire
May 20162098Highwire
Jun 20163113Highwire
Jul 20161720Highwire
Aug 20161523Highwire
Sep 20162010Highwire
Oct 20163520Highwire
Nov 20161844Highwire
Dec 20163277Highwire
Jan 20172031Highwire
Feb 20171402Highwire
Mar 20172546Highwire
Apr 20173901Highwire
May 20172042Highwire
Jun 2017932Highwire
Jul 2017510Highwire
Aug 20171424Highwire
Sep 20171642Highwire
Oct 20171911Highwire
Nov 20171712Highwire
Dec 20172645Highwire
Jan 20183421Highwire
Feb 201829210Highwire
Mar 20181800Highwire
Apr 20185912Highwire
May 20182053Highwire
Jun 20181820Highwire
Jul 20182431Highwire
Aug 20182820Highwire
Sep 20183033Highwire
Oct 20183011Highwire
Nov 20183933Highwire
Dec 20181660Highwire
Jan 20192421Highwire
Feb 20192005Highwire
Mar 20193932Highwire
Apr 20194322Highwire
May 20192533Highwire
Jun 20193511Highwire
Jul 20193911Highwire
Aug 20192722Highwire
Sep 20192411Highwire
Oct 20194043Highwire
Nov 20193210Highwire
Dec 20192900Highwire
Jan 20203801Highwire
Feb 20202202Highwire
Mar 20201354Highwire
Apr 20203111Highwire
May 202022116Highwire
Jun 20201611Highwire
Jul 20202922Highwire
Aug 20201831Highwire
Sep 20201410Highwire
Oct 20201720Highwire
Nov 20202512Highwire
Dec 20201900Highwire
Jan 20214731Highwire
Feb 20211121Highwire
Mar 20214101Highwire
Apr 20213312Highwire
May 20213513Highwire
Jun 20212020Highwire
Jul 20212202Highwire
Aug 20212340Highwire
Sep 20215661Highwire
Oct 20213423Highwire
Nov 20212733Highwire
Dec 20213412Highwire
Jan 20224622Highwire
Feb 20222510Highwire
Mar 20224801Highwire
Apr 20223201Highwire
May 20223011Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me